Daily Cosmetic Research Analysis
A multicenter NEJM randomized trial found no reduction in device failure with hydrophobic or chlorhexidine peripherally inserted central catheters versus standard polyurethane, informing procurement and practice. In cosmetic dermatology, a 1726 nm laser with real-time thermal monitoring achieved selective sebaceous gland photothermolysis and a 71% inflammatory lesion count reduction at 3 months. A bidirectional Mendelian randomization study identified causal links between specific skin microbiot
Summary
A multicenter NEJM randomized trial found no reduction in device failure with hydrophobic or chlorhexidine peripherally inserted central catheters versus standard polyurethane, informing procurement and practice. In cosmetic dermatology, a 1726 nm laser with real-time thermal monitoring achieved selective sebaceous gland photothermolysis and a 71% inflammatory lesion count reduction at 3 months. A bidirectional Mendelian randomization study identified causal links between specific skin microbiota and hypertrophic scar risk, suggesting microbiome-targeted prevention strategies.
Research Themes
- Pragmatic RCTs guiding device selection and safety
- Energy-based dermatologic therapy with real-time thermal control
- Genetic causal inference linking skin microbiota to scarring
Selected Articles
1. A Comparison of Peripherally Inserted Central Catheter Materials.
In a multicenter randomized superiority trial (n=1098), hydrophobic and chlorhexidine-impregnated PICCs did not reduce device failure compared with standard polyurethane catheters over 8 weeks. The chlorhexidine group had higher overall complications, challenging assumptions that antimicrobial-impregnated materials improve outcomes.
Impact: Provides high-level evidence to guide PICC material selection across inpatient care, with immediate implications for procurement and prevention bundles. Negative results prevent low-value adoption.
Clinical Implications: Standard polyurethane PICCs remain appropriate first-line. Focus should remain on insertion technique, care bundles, and surveillance rather than premium materials, and reconsider routine use of chlorhexidine-impregnated PICCs.
Key Findings
- No significant difference in device failure between hydrophobic (5.9%) and standard polyurethane (6.1%) PICCs (risk difference −0.2%, P=0.89).
- Chlorhexidine PICCs showed non-significantly higher device failure (9.9%) and significantly more complications overall versus standard polyurethane (OR 2.35, 95% CI 1.68–3.29).
- Trial included adults and children (n=1098) with 8-week follow-up and no intervention-attributable adverse events; registered (ACTRN12619000022167).
Methodological Strengths
- Multicenter randomized controlled design with large sample size (n=1098).
- Pre-registered trial with clear composite primary endpoint and intention-to-treat analysis implied by NEJM standards.
Limitations
- 8-week follow-up may miss longer-term failures or cost-effectiveness differences.
- Composite endpoint may mask divergent effects on specific complications.
Future Directions: Evaluate cost-effectiveness and longer-term outcomes, and identify subgroups (e.g., high-infection risk) where materials might differ.
BACKGROUND: New catheter materials for peripherally inserted central catheters (PICCs) may reduce the risk of device failure due to infectious, thrombotic, and catheter occlusion events. However, data from randomized trials comparing these catheters are lacking. METHODS: We conducted a randomized, controlled, superiority trial in three Australian tertiary hospitals. Adults and children who were referred for PICC placement were assigned in a 1:1:1 ratio to receive a hydrophobic or chlorhexidine PICC or a standard polyurethane PICC and were followed for 8 weeks. The primary outcome was device failure, which was a composite of infectious (bloodstream or local) or noninfectious (thrombosis, breakage, or occlusion) complications. RESULTS: A total of 1098 participants underwent randomization; 365 were assigned to the hydrophobic group, 365 to the chlorhexidine group, and 368 to the standard-polyurethane group. Device failure occurred in 21 of 358 participants (5.9%) in the hydrophobic group, in 36 of 363 (9.9%) in the chlorhexidine group, and in 22 of 359 (6.1%) in the standard-polyurethane group (risk difference, hydrophobic vs. standard polyurethane, -0.2 percentage points [95% confidence interval {CI}, -3.7 to 3.2; P = 0.89]; and chlorhexidine vs. standard polyurethane, 3.8 percentage points [95% CI, -0.1 to 7.8; P = 0.06]). In the hydrophobic group as compared with the standard-polyurethane group, the odds ratio for device failure was 0.96 (95% CI, 0.51 to 1.78), and in the chlorhexidine group as compared with the standard-polyurethane group, the odds ratio was 1.71 (95% CI, 0.98 to 2.99). Complications from any cause during the period of PICC placement occurred in 77 participants (21.5%) in the hydrophobic group, in 140 (38.6%) in the chlorhexidine group, and in 78 (21.7%) in the standard-polyurethane group (odds ratio, hydrophobic vs. standard polyurethane, 0.99 [95% CI, 0.69 to 1.42]; and chlorhexidine vs. standard polyurethane, 2.35 [95% CI, 1.68 to 3.29]). No adverse events were attributable to the interventions. CONCLUSIONS: Among adults and children who were referred for PICC placement, the risk of device failure due to noninfectious or infectious complications was not lower with hydrophobic or chlorhexidine PICCs than with standard polyurethane PICCs. (Funded by the National Health and Medical Research Council of Australia; PICNIC Australian New Zealand Clinical Trials Registry number, ACTRN12619000022167.).
2. Treatment of Acne With a 1726 nm Laser, Air Cooling, and Real-Time Temperature Monitoring, Software-Assisted Power Adjustment to Achieve a Temperature Endpoint With Selective Sebaceous Gland Photothermolysis.
A novel 1726 nm laser platform with real-time epidermal temperature monitoring and bulk air-cooling achieved selective sebaceous gland photothermolysis at depth, yielding a 71% inflammatory lesion count reduction at 3 months. Two pulsing protocols provided comparable efficacy with differing pain profiles, enabling anesthesia-sparing treatment.
Impact: Introduces a treat-to-temperature, image-guided energy-based therapy for acne that targets sebaceous glands selectively, potentially redefining non-drug approaches with improved safety and patient comfort.
Clinical Implications: Offers a non-systemic, anesthesia-sparing option for moderate acne with histologically confirmed sebaceous gland targeting. Real-time temperature feedback and protocol selection can individualize efficacy and comfort.
Key Findings
- Multi-pulse 1726 nm delivery with bulk air-cooling selectively elevated sebaceous gland temperatures versus dermis, enabling deep photothermolysis unattainable by single pulses.
- Average inflammatory lesion count reduction of 71% at 3 months post-treatment.
- Two pulsing protocols achieved similar sebaceous gland selectivity with markedly different pain responses, reducing the need for injectable anesthesia.
- Histology confirmed deep sebaceous gland damage with preservation of epidermis and surrounding dermis.
Methodological Strengths
- Integration of real-time thermal imaging, bioheat/light transport modeling, and histological validation.
- IRB-approved clinical safety/efficacy trials with defined temperature endpoints and protocol optimization.
Limitations
- Nonrandomized design with unspecified sample size limits generalizability.
- Durability beyond 3 months and comparative effectiveness versus standard therapies remain unknown.
Future Directions: Conduct randomized controlled trials comparing to standard acne therapies, refine dosing by skin type/sebaceous depth, and extend follow-up to 12 months.
OBJECTIVES: This work highlights the methods used to develop a multi-pulse 1726 nm laser system combined with bulk air-cooling for selective sebaceous gland (SG) photothermolysis using thermal imaging and software algorithms. This approach enables treating to a desired tissue temperature and depth to provide a safe, effective, reproducible, and durable treatment of acne. METHODS: We designed and built a 1726 nm laser system with a 40 W maximum power output, a highly controlled air-cooling device, and a thermal camera in the handpiece, which permits real-time temperature monitoring of the epidermis. IRB-approved safety and efficacy trials demonstrated SG damage at depth, resulting in safe, efficacious, and durable clinical outcomes. Bioheat transfer and light transport modeling confirmed that the pulsing protocols could produce therapeutic temperatures at various SG depths, while protecting the epidermis and dermis with bulk air-cooling. Similarly, we employed clinical observations and photothermal modeling to identify pain mitigation opportunities while maintaining therapeutic efficacy. Biopsies were subsequently taken for histological evaluation. RESULTS: Clinical and histological data, confirmed with modeling, demonstrated that multi-pulse laser delivery with bulk air-cooling selectively increased SG temperature compared to surrounding dermis and at depths unachievable by a single pulse. Subjects showed an average 71% ILC reduction at 3 months posttreatment. We identified two different pulsing protocols with similar selective photothermolysis (SP) of the SG with very different pain responses. Thus, changing the pulsing protocols allowed for pain mitigation and eliminated the need for injectable anesthetic. Histology confirmed the selective damaging of the SG at depth and the preservation of the surrounding dermis and the epidermis. CONCLUSIONS: The multi-pulse 1726 nm laser with bulk air-cooling, thermal monitoring, treat-to-temperature (and depth) control, and a unique pulsing protocol, is capable of selectively damaging SGs at depth without damage to the surrounding dermis or the epidermis. The system offers two different protocols that were developed with different levels of discomfort allowing for two different methods for pain mitigation (injectable vs. topical anesthesia).
3. Investigating the causal relationship between skin microbiota and hypertrophic scar using bidirectional mendelian randomization.
Using bidirectional two-sample Mendelian randomization with PopGen and FinnGen GWAS, the study found protective causal effects of Enhydrobacter, Micrococcus, and Acinetobacter (moist skin) and increased risk from Finegoldia and Lactobacillales (dry skin) for hypertrophic scars. Sensitivity analyses showed no horizontal pleiotropy or heterogeneity.
Impact: Provides genetically anchored causal evidence linking skin microbiota to scarring biology, opening a translational path for microbiome-based risk stratification and interventions in HS.
Clinical Implications: Suggests targeting specific taxa through topical probiotics, prebiotics, or antimicrobial stewardship may modulate HS risk, and motivates microbiome-informed postoperative scar care.
Key Findings
- Bidirectional MR identified protective causal effects of Enhydrobacter, Micrococcus, and Acinetobacter on moist skin against hypertrophic scar.
- Finegoldia and Lactobacillales on dry skin were causally linked to increased hypertrophic scar risk.
- Sensitivity analyses (MR-Egger intercept, Cochrane’s Q) found no evidence of horizontal pleiotropy or heterogeneity.
Methodological Strengths
- Two-sample, bidirectional Mendelian randomization across independent GWAS datasets.
- Multiple MR estimators and sensitivity analyses to assess pleiotropy and heterogeneity.
Limitations
- GWAS-based microbiota proxies provide limited taxonomic resolution and may not capture strain-level effects.
- Clinical translation requires validation in prospective cohorts and interventional studies.
Future Directions: Prospective validation linking skin microbiome profiles to HS incidence and trials testing microbiome modulation (e.g., topical probiotics) in high-risk patients.
BACKGROUND: Hypertrophic scar (HS) is acknowledged as a pathological fibro-proliferative disease of the dermis, resulting from excessive connective tissue growth. HS significantly impacts patient quality of life due to both social and functional issues. Despite various treatments, therapeutic effectiveness remains limited, necessitating further exploration of underlying factors and mechanisms. OBJECTIVE: The current study was designed to determine the causal relationship between skin microbiota and HS employing a bidirectional Mendelian randomization (MR) approach. METHODS: We utilized genome-wide association study (GWAS) data from the PopGen cohort and the FinnGen database. Independent single nucleotide polymorphisms (SNPs) linked to the skin microbiota were identified as instrumental variables (IVs) chosen for the two-sample MR analysis. Key analytical approaches included inverse variance weighting (IVW), MR-Egger, simple median, simple mode, and weighted mode, with MR-Egger intercept test and Cochrane's Q test used to detect potential horizontal pleiotropy and heterogeneity. RESULTS: The two-sample MR analysis identified significant causal relationships between specific skin microbiota features and HS. Notably, Enhydrobacter, Micrococcus, and Acinetobacter on moist skin exhibited protective effects against HS, whereas Finegoldia and Lactobacillales on dry skin were linked to an increased risk of HS. Sensitivity analyses verified the strength of these results, revealing no notable horizontal pleiotropy or heterogeneity. CONCLUSION: Our research reveals a unidirectional causal relationship between certain skin microbiota and HS, suggesting that modulation of skin microbiota could be a novel therapeutic approach for HS management. These results emphasize the significance of considering skin microbiota in the pathogenesis and treatment of HS.